These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 31004212)

  • 1. Update on narcolepsy.
    Reading PJ
    J Neurol; 2019 Jul; 266(7):1809-1815. PubMed ID: 31004212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypocretin (orexin) biology and the pathophysiology of narcolepsy with cataplexy.
    Liblau RS; Vassalli A; Seifinejad A; Tafti M
    Lancet Neurol; 2015 Mar; 14(3):318-28. PubMed ID: 25728441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias.
    Mignot E; Lammers GJ; Ripley B; Okun M; Nevsimalova S; Overeem S; Vankova J; Black J; Harsh J; Bassetti C; Schrader H; Nishino S
    Arch Neurol; 2002 Oct; 59(10):1553-62. PubMed ID: 12374492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An overview of hypocretin based therapy in narcolepsy.
    Takenoshita S; Sakai N; Chiba Y; Matsumura M; Yamaguchi M; Nishino S
    Expert Opin Investig Drugs; 2018 Apr; 27(4):389-406. PubMed ID: 29623725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin/orexin system.
    Nishino S; Kanbayashi T
    Sleep Med Rev; 2005 Aug; 9(4):269-310. PubMed ID: 16006155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical spectrum of narcolepsy with cataplexy: a reappraisal.
    Sturzenegger C; Bassetti CL
    J Sleep Res; 2004 Dec; 13(4):395-406. PubMed ID: 15560774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Narcolepsy without cataplexy: 2 subtypes based on CSF hypocretin-1/orexin-A findings.
    Oka Y; Inoue Y; Kanbayashi T; Kuroda K; Miyamoto M; Miyamoto T; Ikeda A; Shimizu T; Hishikawa Y; Shibasaki H
    Sleep; 2006 Nov; 29(11):1439-43. PubMed ID: 17162990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Narcolepsy with hypocretin/orexin deficiency, infections and autoimmunity of the brain.
    Kornum BR; Faraco J; Mignot E
    Curr Opin Neurobiol; 2011 Dec; 21(6):897-903. PubMed ID: 21963829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T cells in patients with narcolepsy target self-antigens of hypocretin neurons.
    Latorre D; Kallweit U; Armentani E; Foglierini M; Mele F; Cassotta A; Jovic S; Jarrossay D; Mathis J; Zellini F; Becher B; Lanzavecchia A; Khatami R; Manconi M; Tafti M; Bassetti CL; Sallusto F
    Nature; 2018 Oct; 562(7725):63-68. PubMed ID: 30232458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The narcoleptic borderland: a multimodal diagnostic approach including cerebrospinal fluid levels of hypocretin-1 (orexin A).
    Bassetti C; Gugger M; Bischof M; Mathis J; Sturzenegger C; Werth E; Radanov B; Ripley B; Nishino S; Mignot E
    Sleep Med; 2003 Jan; 4(1):7-12. PubMed ID: 14592354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypocretin/orexin and sleep: implications for the pathophysiology and diagnosis of narcolepsy.
    Overeem S; Scammell TE; Lammers GJ
    Curr Opin Neurol; 2002 Dec; 15(6):739-45. PubMed ID: 12447114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Type 1 narcolepsy: a CD8(+) T cell-mediated disease?
    Degn M; Kornum BR
    Ann N Y Acad Sci; 2015 Sep; 1351():80-8. PubMed ID: 26096261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The neurobiology of hypocretins (orexins), narcolepsy and related therapeutic interventions.
    Zeitzer JM; Nishino S; Mignot E
    Trends Pharmacol Sci; 2006 Jul; 27(7):368-74. PubMed ID: 16766052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absence of autoreactive CD4
    Kornum BR; Burgdorf KS; Holm A; Ullum H; Jennum P; Knudsen S
    J Neuroimmunol; 2017 Aug; 309():7-11. PubMed ID: 28601291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The hypocretin/orexin system in health and disease.
    Nishino S
    Biol Psychiatry; 2003 Jul; 54(2):87-95. PubMed ID: 12873797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypocretin (orexin) levels in cerebrospinal fluid of patients with narcolepsy: relationship to cataplexy and HLA DQB1*0602 status.
    Krahn LE; Pankratz VS; Oliver L; Boeve BF; Silber MH
    Sleep; 2002 Nov; 25(7):733-6. PubMed ID: 12405608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The hypocretin/orexin receptor: therapeutic prospective in sleep disorders.
    Nishino S
    Expert Opin Investig Drugs; 2007 Nov; 16(11):1785-97. PubMed ID: 17970638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of IV and ICV hypocretin-1 (orexin A) in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin-ligand-deficient narcoleptic dog.
    Fujiki N; Yoshida Y; Ripley B; Mignot E; Nishino S
    Sleep; 2003 Dec; 26(8):953-9. PubMed ID: 14746374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The sleep-wake cycle, the hypocretin/orexin system and narcolepsy: advances from preclinical research to treatment.
    Arias-Carrión O; Bradbury M
    CNS Neurol Disord Drug Targets; 2009 Aug; 8(4):232-4. PubMed ID: 19689304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypocretins (orexins) and sleep-wake disorders.
    Baumann CR; Bassetti CL
    Lancet Neurol; 2005 Oct; 4(10):673-82. PubMed ID: 16168936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.